ATSN-101 demonstrated clinically meaningful improvements in …
Born from the Foundation Fighting Blindness, the RD (Retinal Degeneration) Fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the Foundation Fighting Blindness is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Together, these blinding conditions affect more than 200 million people throughout the world.
The RD Fund is changing how the world treats blinding retinal diseases.
Click here to download the January 2022 Outcomes & Outlook Report.
IN THE NEWS
09/27/2022
Opus Genetics Expands Board of Directors with Appointment of Global…
RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE…
09/15/2022
RD Fund Participates in a €75 Million Series B for SparingVision
Proceeds to fund first, in-human trials of breakthrough gene…
08/12/2022
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Pa…
- In line with corporate strategy update in April, ProQR to f…
07/27/2022
Atsena Therapeutics Announces Opening of New Office and Laboratory…
World-class facility supports the company’s growth, and disc…
07/21/2022
Opus Genetics Expands its Leadership Team
Vikram Arora, Ph.D., DABT, appointed Vice President of Non-C…
07/21/2022
RD Fund Announces New Chair, and Expansion of Board of Directors
RD Fund Board member and seasoned ophthalmology leader Adrie…
07/11/2022
Opus Genetics to Present at OIS Retina Innovation Summit 2022
Opus Genetics, a patient-first gene therapy company developi…
06/21/2022
Foundation Fighting Blindness Announces Leadership Changes
Jason Menzo named chief executive officer
Russell Kelley, Ph…
06/15/2022
Nacuity Pharmaceuticals Announces $16.5 Million Series B Financing…
Funds to support advancement of two clinical trials t…
05/11/2022
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
Biopharma clinical development veteran to propel Opus’ AAV-b…
03/08/2022
Foundation Fighting Blindness and InformedDNA Partner to Engage and…
Trial recruitment is enabled by the Foundation Fighting Blin…